

☒ Trademarks or ☐ Patents. (☐ the patent action involves 35 U.S.C. § 292.);

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

In the above—entitled case, the following decision has been rendered or judgement issued:

CLERK Patricia L. McNutt	(BY) DEPUTY CLERK A. Foster	DATE 8/18/11
-----------------------------	--------------------------------	-----------------



US006403649B1

(12) United States Patent
Woodward et al.**(10) Patent No.: US 6,403,649 B1**
(45) Date of Patent: *Jun. 11, 2002**(54) NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS****(75) Inventors:** David F. Woodward, El Toro; Steven W. Andrews, Rancho Santa Marguerita; Robert M. Burk, Irvine; Michael E. Garst, Newport Beach, all of CA (US)**(73) Assignee:** Allergan Sales, Inc., Irvine, CA (US)**(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 09/519,834**(22) Filed:** Mar. 6, 2000**Related U.S. Application Data****(60)** Continuation of application No. 08/876,937, filed on Jun. 16, 1997, which is a continuation of application No. 08/605,567, filed on Feb. 22, 1996, now Pat. No. 5,688,819, which is a continuation-in-part of application No. 08/371,339, filed on Jan. 11, 1995, now Pat. No. 5,607,978, which is a continuation of application No. 08/154,244, filed on Nov. 18, 1993, now abandoned, which is a division of application No. 07/948,056, filed on Sep. 21, 1992, now Pat. No. 5,352,708.**(51) Int. Cl.⁷** A61K 31/135**(52) U.S. Cl.** 514/646; 564/171; 564/189**(58) Field of Search** 514/530, 546, 514/548, 555, 570, 913, 646; 560/53, 60, 255; 562/452, 465; 564/171, 189**(56) References Cited****U.S. PATENT DOCUMENTS**

4,055,602 A	10/1977	Nelson
4,097,489 A	6/1978	Bundy
4,128,713 A	12/1978	Schneider
4,131,738 A	12/1978	Smith
4,171,331 A	10/1979	Biddlecom et al.
4,183,870 A	1/1980	Caton et al.
4,444,788 A	4/1984	Skuballa et al.
4,599,353 A	7/1986	Bito
4,994,274 A	2/1991	Chan et al.
5,034,413 A	7/1991	Chan et al.
5,352,708 A	10/1994	Woodward et al.
5,414,016 A	5/1995	Skuballa et al.
5,510,383 A	4/1996	Bishop et al.
5,545,665 A	8/1996	Burk
5,587,391 A	12/1996	Burk
5,607,978 A	3/1997	Woodward et al.

FOREIGN PATENT DOCUMENTS

CA	2036386	1/1991
CS	271137	* 8/1990
DE	27 21 534	12/1977
EP	0 093 380	11/1983

EP	0 102 230	7/1984
EP	0 253 094	1/1988
EP	0 364 417	1/1989
EP	0 453 127	10/1991
FR	2 312 240	12/1976
FR	2 386 523	11/1978
FR	2 402 644	3/1979
LU	68 940	2/1974
WO	90/02553	3/1990
WO	92/08465	5/1992

OTHER PUBLICATIONS

Prostaglandins: vol. 13, No. 5, May 1977, Stoneham, MA, pp. 837-843, H.C. Arndt, "The Synthesis and Biological Activity of Prostaglandins Analogs Containing Spirocyclic Rings".

Tetrahedron: Vol. 32, 1976, Oxford GB, pp. 2747-2752, P. De Clercq et al., "Cyclopentanones-XVI. Prostaglandin Synthesis Involving Catalytic Hydrogenation of 2,3-Dialkyl-4-Hydroxy-2-Cyclopentenones".

Derwent Pub. Lts. London GB AN 71-57225 & JPA, 46 030 830, Ono Pharmaceutical Co., Sep. 7, 1971.

Bito, L.Z., "Prostaglandins and Related Compounds as Potential Ocular Therapeutic Agents", Biological Protection with Prostaglandins (Cohen, M.M., ed., Boca Raton, FL, CRC Press Inc., 1985, pp. 231-252.

Bito, L.Z., "Prostaglandins, Old Concepts and New Perspectives," Arch Oph., vol. 105, Aug. 1987 p. 1036-1039.

Starr, M.S., "Further Studies on the Effect of Prostaglandin on Intraocular Pressure in the Rabbit", Exp. Eye Res., (1971) 170-177.

Nilsson, Siv F.E., et al., "PGF_{2a} Increases Uveoscleral Outflow", ARVO Abstract, p. 284, Invest. Ophthalmol. Vis. Sci. 28 (suppl) (1987).

Bito, L.Z., "Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents", Applied Pharmacology in the Medical Treatment of Glaucoma, pp. 477-505, 1984.

* cited by examiner

Primary Examiner—Sreeni Padmanabhan

(74) Attorney, Agent, or Firm—Robert J. Baran; Martin A. Voet; Carlos A. Fisher

(57) ABSTRACT

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

3 Claims, No Drawings